Skip to content
Annika Bansal – Lifestyle
Author:
Artios Pharma
Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer
May 26, 2026
Artios Announces Clinical Trial Collaboration with GSK to Evaluate Alnodesertib in Combination with Risvutatug Rezetecan, a B7-H3-Targeted ADC in Gastrointestinal Tumors
May 12, 2026
Artios Further Expands Leadership Team to Advance Oncology Pipeline and Accelerate Regulatory Execution
May 4, 2026
Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer
March 5, 2026